Various statements in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including words such as, but not limited to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,” “design,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “predict,” “project,” “target,” “likely,” “should,” “will,” and “would,” or the negative of these terms and similar expressions or words, identify forward-looking statements. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. The information that Checkmate Pharmaceuticals posts on these channels and websites could be deemed to be material information. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. Investors and others should note that we communicate with our investors and the public using our website (our investor relations website (ir.), and on social media (Twitter and LinkedIn), including but not limited to: investor presentations and investor fact sheets, U.S. Information regarding Checkmate Pharmaceuticals is available at Availability of Other Information About Checkmate Pharmaceuticals Checkmate Pharmaceuticals’ product candidate, vidutolimod (CMP-001), is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle utilizing a CpG-A oligodeoxynucleotide as a key component, designed to trigger the body’s innate immune system to attack tumors in combination with other therapies. in both Business Administration and Agricultural Economics from Montana State University.Ĭheckmate Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. Fuhrman practiced as a certified public accountant with Coopers & Lybrand. He previously served as CFO of Ambit Biosciences, where he helped lead the company through its initial public offering and oversaw financial, investor and administrative operations until its sale to Daiichi Sankyo in 2014. Prior to joining Amplyx, he served as CFO of Mirna Therapeutics, a publicly traded, clinical-stage microRNA company that merged with Synlogic in August 2017. He previously served as the Chief Financial Officer of Amplyx Pharmaceuticals, Inc. Fuhrman also served on the Board of Directors and as Chair of the Audit Committee for Loxo Oncology until its sale to Eli Lilly in the first quarter of 2019. He is a member of the Board of Directors for SpringWorks Therapeutics and Esperion Therapeutics. Fuhrman is an experienced financial operations leader with a focus on guiding the growth of innovative pharmaceutical and biotechnology companies. The Board has initiated a candidate search to identify a permanent CEO. “On behalf of the entire Board, I want to thank Barry for his contributions to Checkmate, and we wish him much success with his future endeavors,” said Mike Powell, Chairman of the Board of Directors. Our strategic priority is to rapidly advance our vidutolimod clinical program toward meaningful clinical data, and I am excited to lead the Company at this important time,” said Alan Fuhrman, interim President and CEO. “We believe that vidutolimod has significant potential as a novel investigational therapeutic for melanoma and other difficult to treat tumor types. Fuhrman succeeds Barry Labinger, who has transitioned from his roles as President and CEO and Director. (Nasdaq: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Alan Fuhrman has been appointed as interim President and CEO.
27, 2021 (GLOBE NEWSWIRE) - Checkmate Pharmaceuticals, Inc.
0 kommentar(er)
